标题:Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B
作者:Shao-bo.Cui;Rong-hua.Shu;Shi-ping.Yan;Hao.Wu;Yong.
作者机构:[Cui, S.-B] Department of Gastroenterology, Provincial Hospital Affiliated to Shandong University, 324, Jing 5 Rd, Jinan, Shandong Province, 250021, C 更多
通讯作者:Zhu, Q
通讯作者地址:[Zhu, Q]Shandong Univ, Prov Hosp, Dept Gastroenterol, 324,Jing 5 Rd, Jinan 250021, Shandong, Peoples R China.
来源:European Journal of Gastroenterology & Hepatology
出版年:2015
卷:27
期:8
页码:914-919
DOI:10.1097/MEG.0000000000000351
关键词:anticoagulation therapy;cirrhosis;different doses;enoxaparin;low-molecular-weight heparin;portal vein thrombosis
摘要:BACKGROUND: Patients with cirrhosis have a high incidence of portal vein thrombosis (PVT), and optimal management of PVT in cirrhotic patients remains unclear. Currently, there is no paper on optimal doses of enoxaparin for the management of PVT with cirrhosis. AIMS: To evaluate the efficacy and safety of anticoagulation therapy with different doses of enoxaparin for PVT in cirrhotic patients with hepatitis B. MATERIALS AND METHODS: Sixty-five patients with hepatitis B-related cirrhosis and acute PVT were treated by different doses of enoxaparin. All the patients were assigned randomly to two groups: one group received enoxaparin 1 mg/kg subcutaneously every 12 h and the other group received enoxaparin 1.5 mg/kg subcutaneously every 24 h. Clinical, biochemical evaluation, Doppler ultrasound, and contrast-enhanced computed tomography were performed during the anticoagulation treatment. RESULTS: Of the 65 patients, 51 patients (78.5%) achieved complete/partial recanalization of PVT after 6 months of anticoagulation therapy. Child–Pugh scores were lower in the 51 patients who achieved complete/partial recanalization than those of the 14 nonresponders (P
收录类别:SCOPUS;SCIE
WOS核心被引频次:16
Scopus被引频次:19
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929374888&doi=10.1097%2fMEG.0000000000000351&partnerID=40&md5=354aafef47f80c20a3704ca0fd0cff1e
TOP